Michael Tjong

147 posts

Michael Tjong

Michael Tjong

@mctjong

#RadOnc @Sunnybrook @UofTDRO. Likes: 🍣 🎾 ⚽️. Dislikes: cancers. Tweets are my own.

Toronto, Ontario Katılım Temmuz 2020
136 Takip Edilen219 Takipçiler
Michael Tjong retweetledi
arjun sahgal
arjun sahgal@SahgalArjun·
Kudos to our @Sunnybrook medical physics, electronics and therapy team as we have successfully installed the Varian ETHOS as the 1st of 2 matched units. Critical step as we transform our department to realize the Cancer Ablation Adaptive Therapy (CAAT) Program mission.
arjun sahgal tweet media
English
1
3
39
1.2K
Michael Tjong retweetledi
Shankar Siva
Shankar Siva@_ShankarSiva·
#ESTRO26 - 📣 FASTRACKII final results, median F/U of 5 years. Thank you patients, funders, investigators - #kidneycancer #kcsm 1) 100% Local Control: No local recurrences were observed at 36, 60, or 84 months. 2) 100% Cancer-Specific Survival 3) Grade 3 AEs remain at 10%
Shankar Siva tweet media
English
9
109
190
31.1K
Michael Tjong retweetledi
David Sher
David Sher@DavidSherMD·
Absolutely terrific work by @DrSymYoung to report the long-term outcomes of our INRT experience from two prospective trials (INRT-AIR and DARTBOARD). Short version: with long-term follow-up (median 5.2 years for INRT-AIR, 3 years for DARTBOARD), we've seen zero solitary elective nodal recurrences. Longer version: ESTRO has highlighted novel approaches to managing the elective neck in HNSCC, and I believe the future will be very different than the present. Current ENI fields deliver the majority of the integral dose to patients and contribute substantially to critical structures (swallowing and xerostomia OARs). Minimizing ENI dose and volume may meaningfully improve the short- and especially long-term tolerance of radiotherapy. A few more thoughts on our INRT paradigm below:
OncoAlert@OncoAlert

Day FOUR of #ESTRO26 Coverage by OncoAlert 🚨 Omission of elective nodal irradiation in HNSCC: long-term results and patient-level pooled analysis from 2 prospective trials (INRT-AIR & DARTBOARD) Presenter Sympascho Young 🇺🇸 A patient-level pooled analysis of 117 patients from two prospective trials (INRT-AIR and DARTBOARD) showed that omission of elective nodal irradiation for HNSCC was oncologically safe long-term, with a 0% rate of solitary elective nodal recurrence at 5 years. The trials used an involved nodal radiotherapy (INRT) approach assisted by an artificial intelligence model for detection of suspicious nodes. @DrSymYoung @DavidSherMD #RadOnc @ESTRO_RT @yasemin09896924 @LindaMrissa @christian_roenn @Valeriadionisi @gerryhanna @clchiang_hk @mtugceyilmaz @B_Tomasik @gmpetrianni @CiroFranzese1 @Atem84 @piet_ost @brachyexpert @BlanceS90 @The_PT_Explorer @BarbaraJereczek @Mat_Guc @ZilliThomas @AnnaKirby17 @PBlanchardMD @achoud72 Pinging OA faculty @MKnoll_MD @_ShankarSiva @Icro_Meattini @seanmmcbride @NiuSanford @nataliagandur @acampsmalea @to_be_elizabeth

English
2
31
58
6.7K
Michael Tjong retweetledi
Nadeem Riaz
Nadeem Riaz@xrtGenomics·
Great letter by @SeanMcbride laying out real concerns with the OS claim in @SJFrankMD's proton vs. photon oropharynx trial. Compelling enough that Yingzhi Wu and @EChrisDee pulled our own data. We see no OS difference between protons and photons. Together with UK TORPEdO RCT, this adds to the concern that the randomized trial’s OS finding may be hypothesis-generating rather than causal.
Nadeem Riaz tweet media
Sean McBride@seanmmcbride

Our letter to the editor in The Lancet critiquing the MD Anderson-led trial of protons v photons for OPC. Appreciate @SJFrankMD's well thought out response. I think we can all agree on two points: 1) Steve deserves major kudos for bringing level 1 evidence to the debate on protons v photons for OPC. These trials are extraordinarily difficult to run, and Steve, et al pulled it off. Well done! 2) Longer term follow-up from TORPEdO will help tease out the extent to which protons improves OS in OPC. @CJTsaiMDPhD @drlorenmell @xrtGenomics @DavidSherMD #radonc #hncsm thelancet.com/journals/lance…

English
4
17
41
6.9K
Michael Tjong retweetledi
arjun sahgal
arjun sahgal@SahgalArjun·
The entire @Sunnybrook spine #SBRT team has come together to share 17 years of research and clinical observations in this review for @NatRevClinOncol. We are a true multidisciplinary team that have had a singular focus to develop the technique and evidence nature.com/articles/s4157…
arjun sahgal tweet media
English
3
46
114
4.5K
Michael Tjong retweetledi
Advances, an ASTRO Journal
Advances, an ASTRO Journal@Advances_ASTRO·
📌 Cardiac Dose and Survival Outcomes Following SBRT for Primary and Metastatic Lung Tumors: A Substructure-Based Analysis 🔗 advancesradonc.org/article/S2452-… @ASTRO_org @ChariteBerlin 👉🏻 Dose–response relationships are driven by cardiac substructures rather than by whole-heart exposure. 👉🏻Elevated EQD₂ doses to upper cardiac structures, such as the left atrium and superior vena cava, were independently associated with reduced overall survival. 👉🏻 There was a trend toward decreased survival with higher doses to the cardiac base, indicating a consistent vulnerability of this region.
Advances, an ASTRO Journal tweet mediaAdvances, an ASTRO Journal tweet mediaAdvances, an ASTRO Journal tweet mediaAdvances, an ASTRO Journal tweet media
English
1
24
54
3.6K
Michael Tjong retweetledi
Alexander Rühle
Alexander Rühle@RuehleAlex·
🔥 Hot off the press: "Prognostic Value of Impaired Vocal Cord Mobility in T2N0 Glottic Cancer Treated With IMRT" ➡️In T2N0 glottic cancer, impaired vocal cord mobility is associated with worse LRF (aHR 3.7) and DFS (aHR 2.7) doi.org/10.1002/lary.7… @PMResearch_UHN @UofTDRO
English
4
13
32
5.4K
Michael Tjong retweetledi
Amir Safavi
Amir Safavi@safaviaa·
Similar model in last few years at @Sunnybrook #hncsm #radonc (not just NPC) w/ 1:1 RD + MD pairing from pre-treatment through follow-up with proactive weekly RD assessments during on-treatment review visits. Requires support as volumes and team grow but a worthwhile venture.
English
0
4
8
1.8K
Michael Tjong retweetledi
Drew Moghanaki
Drew Moghanaki@DrewMoghanaki·
That’s David Harpole at #WCLC25 pointing out that with 70% already accrued to the VALOR study, more than 120 participants have already completed their 5y follow-up period. #CSP2005
Drew Moghanaki tweet media
English
2
7
37
2.9K
Michael Tjong retweetledi
Jeff Ryckman
Jeff Ryckman@jryckman3·
Honored to support the very first World Radiotherapy Awareness Day today, September 7th! 🌍 By working together, we can ensure every person facing cancer has access to life-saving radiotherapy. #WorldRTDay @CamdenClarkMC 📚 Learn more: worldradiotherapy.org
Jeff Ryckman tweet media
English
4
13
33
2.7K
Michael Tjong retweetledi
Dr. Antonio Calles 🫁🚭
Dr. Antonio Calles 🫁🚭@Tony_Calles·
☢️ Finally published the High-Dose Versus Standard-Dose Twice-Daily Thoracic Radiotherapy for LS-SCLC. ✅OS 43.5 versus 22.5 mo, (HR 0.68, 95% CI 0.48–0.98, p = 0.037) No more acute or late onset toxicity. ✅ Would you now consider 60 Gy bid the new standard of care? #LCSM @SclcSMASHERS ovid.com/journals/jton/…
English
4
31
67
8.1K
Michael Tjong retweetledi
Drew Moghanaki
Drew Moghanaki@DrewMoghanaki·
Nasser Altorki's team publishes new data investigating the role of preop SBRT for NSCLC. This time, reporting their institutional data comparing preop SBRT-IO vs Chemo-IO. The results demonstrate a significant association with improved RFS at 2 years with SBRT delivered BEFORE immunotherapy (92% vs 64%, HR = 0.19). Technique = 8 Gy x 3, omiting the LNs doi.org/10.1016/j.jtcv…
Drew Moghanaki tweet media
English
5
19
47
5.4K
Michael Tjong retweetledi
Stephen Lecce
Stephen Lecce@Sflecce·
It hit home as I returned to @Sunnybrook, where my own mother received cancer treatment with a message of HOPE to all who fight this disease. To help the more than 247,000 Canadians this year alone who will be diagnosed with cancer, I was proud to announce an ambitious plan to double the production of life-saving medical isotopes by 2030. Nuclear isotopes produce the essential treatments that help to destroy tumors and diagnose cancers earlier. The Nuclear Isotope Innovation Council of Ontario will save lives and create jobs — a legacy we can all get behind.
Stephen Lecce tweet media
Stephen Lecce tweet media
English
2
9
19
1.9K

Keşfet

@Sunnybrook @DrSymYoung @SeanMcbride @SJFrankMD @EChrisDee @TheLancetOncol @UofTDRO @imrtlee